<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Abstract This paper will review knowledge derived from the introduction of the concept of in situ follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) </plain></SENT>
<SENT sid="1" pm="?"><plain>The following questions will be addressed: 1) how should in situ <z:hpo ids='HP_0002665'>lymphomas</z:hpo> be defined and diagnosed </plain></SENT>
<SENT sid="2" pm="?"><plain>2) is in situ <z:hpo ids='HP_0002665'>lymphoma</z:hpo> an early step of <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> </plain></SENT>
<SENT sid="3" pm="?"><plain>3) is the concept of early <z:hpo ids='HP_0002664'>neoplasia</z:hpo> applicable to the <z:hpo ids='HP_0002665'>lymphoma</z:hpo> setting </plain></SENT>
<SENT sid="4" pm="?"><plain>4) how should patients with in situ <z:hpo ids='HP_0002665'>lymphoma</z:hpo> be managed </plain></SENT>
<SENT sid="5" pm="."><plain>The commonly used term of in situ FL, also called FL in situ (FLIS) has been adopted to define a B-cell lymphoid <z:hpo ids='HP_0002664'>neoplasia</z:hpo> with an intrafollicular growth pattern </plain></SENT>
<SENT sid="6" pm="."><plain>The neoplastic B cells are localized within the germinal center, without invasion of surrounding structures </plain></SENT>
<SENT sid="7" pm="."><plain>Pathological diagnosis requires recognizing strong immunostaining of BCL2 and CD10 by neoplastic B cells inside the affected follicles </plain></SENT>
<SENT sid="8" pm="."><plain>FISH analysis for t(14;18) is mandatory in doubtful cases in which immunohistochemistry data are ambiguous </plain></SENT>
<SENT sid="9" pm="."><plain>In situ FL is probably the earliest stage of development of FL, while the concept of "early" <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is applicable when minimal disease extends beyond the boundaries of the follicular compartment </plain></SENT>
<SENT sid="10" pm="."><plain>From a clinical point of view, in situ FL has an uncertain clinical behaviour and unknown risk to progression to overt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>How to approach and monitor patients with in situ FL is presently uncertain </plain></SENT>
<SENT sid="12" pm="."><plain>An asymptomatic patient with Stage 1 in situ FL requires the same treatment plan as an asymptomatic patient with Stage 1 conventional FL </plain></SENT>
<SENT sid="13" pm="."><plain>For patients with concomitant overt <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, therapy must be applied according to the malignant counterpart </plain></SENT>
</text></document>